echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Professor Liu Yingbin's team revealed that long-term exposure to soy isoflavone genistein inhibits the proliferation of gallbladder cancer and its molecular mechanism Science Bulletin

    Professor Liu Yingbin's team revealed that long-term exposure to soy isoflavone genistein inhibits the proliferation of gallbladder cancer and its molecular mechanism Science Bulletin

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Gallstones have a prevalence of up to 10% worldwide (second only to hypertension and diabetes), and are considered to be the most important risk factor for gallbladder cancer
    .

    Current studies have confirmed that dietary factors are involved in the occurrence and development of gallbladder cancer from gallstones, and play an important role
    .

    However, the dietary structure and habits of different countries in the world are very different, and there is still a lack of relevant research on dietary factors in China and the risk of gallbladder cancer and disease progression
    .

    Recently, Professor Liu Yingbin, Director of the Department of Gallbladder and Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and Director of Shanghai Cancer Institute, and his team published a paper entitled "Long-term exposure to genistein inhibits the proliferation of gallbladder cancer by downregulating" in Science Bulletin.
    the MCM complex", concluded that long-term exposure to the soy isoflavone genistein associated with the Chinese characteristic diet was associated with a lower risk of gallbladder cancer; Its proliferation level is inhibited
    .

    Based on a case-control study of 85 patients with gallbladder cancer and 1:1 matched patients with gallbladder stones, this paper found that high plasma levels of soy isoflavone genistein were associated with a lower risk of gallbladder cancer (≥ 326.
    0 ng/ml vs ≤ 19.
    3 ng/ml) , OR value = 0.
    15, 95% confidence interval 0.
    04–0.
    59; P value for trend test = 0.
    016), and the level of genistein exposure was negatively correlated with Ki67 expression in gallbladder cancer tissues (85 cases)
    .

    Consistent with these results, the proliferation of gallbladder cancer cells was inhibited in long-term genistein exposure models in vitro and in vivo
    .

    The possible mechanism is that gallbladder stones combined with ERBB2 activation promote their transition to gallbladder cancer, while long-term exposure to genistein reduces the tyrosine kinase activity of ERBB2 and affects the function of the PTK6-AKT-GSK3β axis, resulting in gallbladder cancer cells.
    Expression of the MCM complex was downregulated
    .

    The exposure level of soy isoflavone genistein (GEN) is negatively correlated with the proliferation of gallbladder cancer and its possible regulatory mechanism This study draws the conclusion using a multicenter case-control study, and validates the conclusion possibility and related molecules in in vivo and in vitro long-term exposure models mechanism
    .

    This paper expounds the relationship between the long-term exposure of genistein related to soy product intake and the risk of gallbladder cancer, and verifies the effect of long-term exposure to genistein on gallbladder cancer cells from the molecular mechanism level
    .

    The conclusions of this study provide a feasible plan for the prevention and control of gallbladder cancer
    .

    Postdoctoral fellow Geng Yajun from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dr.
    Shili Chen from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dr.
    Yang Yang and Dr.
    Miao Huijie from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine are the co-first authors of this article author
    .

    Researcher Li Maolan from Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Associate Researcher Zhang Wei from the Epidemiology Laboratory of Shanghai Cancer Institute, Professor Shao Rong from the Department of Pharmacy, Shanghai Jiaotong University School of Medicine, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine Deputy Chief Physician Wu Wenguang and Professor Liu Yingbin are the co-corresponding authors of the article
    .

    This article was funded by the National Natural Science Foundation of China, the Shanghai Science and Technology Commission and the State Key Laboratory of Oncogenes and Related Genes
    .

    For details of the research, please read the original text▼[Click the link below or read the original text] https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.